Abbott Laboratories Trading Volume Hits $10.85 Billion Ranking 57th in Market Activity

On May 19, 2025, Abbott Laboratories (ABT) saw a trading volume of $10.85 billion, ranking 57th in the day's stock market activity. The stock rose by 0.56%, marking its third consecutive day of gains, with a total increase of 5.44% over the past three days.

Abbott Laboratories recently presented findings from its REFLECT real-world studies, indicating that the use of its FreeStyle Libre continuous glucose monitoring (CGM) system is associated with a significant reduction in hospitalizations for heart-related complications among individuals with diabetes. This breakthrough demonstrates that CGM technology can mitigate the severity of cardiovascular issues in Type 1 diabetes patients, regardless of their history with low blood sugar or previous heart-related hospital stays. Similarly, the studies showed a decrease in heart-related hospital admissions for Type 2 diabetes patients using the Libre biowearable device while on insulin.

Diabetes affects 589 million people globally, and managing blood sugar levels to prevent complications like heart disease is a critical challenge. Ramzi Ajjan, a professor of Metabolic Medicine at Leeds University and Leeds Teaching Hospitals Trust, commented on the development, expressing excitement over the data showing a significant reduction in cardiovascular disease-related hospital admissions. He highlighted the positive impact of FreeStyle Libre technology on cardiovascular outcomes, making diabetes management more effective and improving patients' health.